SUBJECTS AND METHODS
Patient selection and baseline characteristics
Patients were admitted to the study if they (1) were hospitalized with a diagnosis of variant angina pectoris with a transient ischemic ST-segment elevation of more than 0.1mV during anginal attacks, (2) had two or more anginal attacks during the 2-day pre-observation period, (3) responded with a relief of angina to sublingual nitroglycerin, (4) presented with no clinical findings indicative of acute myocardial infarction or a history of lifethreatening arrhythmia with loss of consciousness, and (5) had given informed consent for participation in the study. Excluded from the study were patients with: 1) anemia or valvular heart disease, and 2) conduction disorders such as left bundle branch block or WPW syndrome. 2. Clinical trial procedure A placebo control period (for a minimum of 2 days) was followed by two treatment periods, which lasted at least 3 days. During the first dose period, the patients received a single daily dose of 10mg nitrendipine.
During the second dose period, a single 20mg daily dose was administered.
The times of drug administration were selected at the discretion of the attending physician. The duration of administration in either treatment period did not exceed 1 week. Other antianginal drugs were not allowed during the study. The efficacy of the drug was evaluated on the basis of frequency of anginal attacks and Holter electrocardiographic findings. Twenty-four hour continuous Holter monitoring was performed in 20 patients during the control (placebo) and second treatment periods and in 15 patients during the first treatment period. The mean times of dosing were 8.4 p.m. (8 p.m. to 9 p.m.) during the first and the second treatment periods in a majority of cases. 4. Twenty-four hour Holter electrocardiograph Twenty-four hour EGG was recorded at most study sites with an Avionics Holter electrocardiograph.
The ECG was recorded through 2 channels, one of them where the maximum ST-segment elevations were observed. The same leads were used in the control and treatment periods. The time of attacks and their relationship to daily activities were recorded by the patients. A positive ST-segment elevation was defined as an elevation of this segment of 1mm (0.1mV) or more lasting at least 60sec.
Statistical analysis
The Wilcoxon sign rank test was used to compare control and treatment period data concerning the ST-segment elevation in the ECG, the frequency of anginal attacks and the consumption of sublingual nitroglycerin tablets. All significance levels were calculated for two-tailed tests.
RESULTS
Effects on subjective symptoms: Figure 1 shows the frequency of anginal attacks and the consumption of sublingual nitroglycerin before and after administration of nitrendipine. Fig. 1 In variant angina pectoris the angina is often unstable. Since the frequency of attacks is inconsistent, patients may die suddenly of acute myocardial infarction or arrhythmias.
Thus, patients with either an impending infarction or life-threatening arrhythmias associated with syncope must be excluded from the clinical trials and observation periods must be minimized. Since few cases satisfy criteria for patient selection necessary to assay the therapeutic effect of new antianginal agents,8) this study involved multiple centers (see Appendix).
In variant angina pectoris, the incidence of ST-segment elevation is independent of anginal symptoms.9)-11) In our study ST-segment elevation was not accompanied by anginal symptoms in 45.6% of cases. Therefore, continuous ECG recording over many hours is essential for evaluating responses to therapy in variant angina pectoris. Holter monitoring is a simple method for evaluating ST-segment elevation in such a patient.12)
Efficacy of nitrendipine:
The mean number of anginal attacks in this study was 2.1 per day and the mean frequency of ST-segment elevation was 4.5 per day. Eleven of the 18 patients undergoing coronary angiography had significant organic coronary stenosis and the other 7 had normal or nearly normal coronary arteries. This group of patients was not considered to be biased toward less severe cases on the basis of reports of coronary artery lesions published in Japan.1), 13) The frequency of anginal attacks and amount of sublingual nitroglycerin consumed decreased significantly during treatment periods I and II. The nitrendipine treatment produced a marked decrease in anginal attacks in 50% of the 21 patients in treatment period I and in 85% of cases in treatment period II. The efficacy of nitrendipine was 72.2% in the former and 90.0% in the latter period. Our previous trials of nifedipine, diltiazem and verapamil in variant angina pectoris showed an efficacy rate of 92.5% with a marked improvement in 71.3% of those patients. This is comparable with the published efficacy rates of nicorandil (87.5%)8) and nilvadipine (92.5%).14)
The frequency, duration and magnitude of ST-segment elevation were reduced or shortened during nitrendipine therapy. Nifedipine, nicorandil and nilvadipine require t.i.d. or b.i.d. administration. By contrast, nitrendipine is a long-acting drug that is administered only once daily and that suppresses ST-segment elevation for at least 10 hours. The plasma concentra- 
